APA (7th ed.) Citation

DS, H., MO, B., RK, P., R, S., P, K., S, B., . . . PM, F. (2022). Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Frontiers in oncology, 12, 818679. https://doi.org/10.3389/fonc.2022.818679

Chicago Style (17th ed.) Citation

DS, Hong, et al. "Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors." Frontiers in Oncology 12 (2022): 818679. https://doi.org/10.3389/fonc.2022.818679.

MLA (9th ed.) Citation

DS, Hong, et al. "Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors." Frontiers in Oncology, vol. 12, 2022, p. 818679, https://doi.org/10.3389/fonc.2022.818679.